Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359).
A 77-year-old woman developed a diffuse nodular eruption with histologic, ultrastructural, and biologic evidence of cutaneous T-cell lymphoma (CTCL) limited to the skin. She was treated with a new aromatic retinoid Ro 10-9359 (1 mg/kg/day). After 34 days, the lesions flattened completely and the mononuclear cell infiltrate decreased significantly. No clinical recurrences occurred after a 4-month survey. Discontinuation of the aromatic retinoid led to a relapse with identical clinical and histologic features.
D000368:Aged; D005050:Etretinate / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013601:T-Lymphocytes; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate